Methods and compositions for modulating IRE1, SRC, and ABL activity
Disclosed herein are, inter alia, compositions for modulating Ire1, Src, or Abl, methods for identifying modulating activity in test compounds, and methods for treating diseases caused by the activity or inactivity of Ire1, Src, or Abl.
1. A compound having the formula:
wherein,
R 1 is hydrogen,
halogen, —CN, —NO, —NO 2 , —NR 9 R 10 , —OR 11 , —COOR 12 , —SR 13 , —COR 14 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R 9 , R 10 , R 11 , R 12 , R 13 , and R 14 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
L is —NH—C(O)—NH—;
A is aryl or heteroaryl;
R 37 is halogen, —CN, —CF 3 , —OH, —NH 2 , —SO 2 , —COOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and
w is an integer from 0 to 5.
2. The compound of claim 1 , wherein R 1 is substituted or unsubstituted C 1 -C 5 alkyl, substituted or unsubstituted 2 to 5 membered heteroalkyl, substituted or unsubstituted C 3 -C 6 cycloalkyl, substituted or unsubstituted 5 or 6 membered heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl.
3. The compound of claim 1 , having the formula:
4. The compound of claim 1 , having one of the following formulae:
5. The compound of claim 1 , wherein R 1 is cyclopropyl.
6. The compound of claim 1 , wherein A is aryl.
7. The compound of claim 1 , wherein A is phenyl.
8. The compound of claim 1 , wherein A is a fused ring aryl or fused ring heteroaryl.
9. The compound of claim 1 , wherein R 37 is halogen, —CN, —CF 3 , —OH, —NH 2 , —SO 2 , —COOH, R 40 -substituted or unsubstituted alkyl, R 40 -substituted or unsubstituted heteroalkyl, R 40 -substituted or unsubstituted cycloalkyl, R 40 -substituted or unsubstituted heterocycloalkyl, R 40 -substituted or unsubstituted aryl, or R 40 -substituted or unsubstituted heteroaryl; and R 40 is
halogen, —CN, —CF 3 , —OH, —NH 2 , —SO 2 , —COOH, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, or unsubstituted heteroaryl.
10. The compound of claim 9 , wherein R 40 is
halogen, —CN, —CF 3 , —OH, —NH 2 , —SO 2 , —COOH, unsubstituted C 1 -C 8 alkyl, unsubstituted 2 to 8 membered heteroalkyl, C 3 -C 7 unsubstituted cycloalkyl, unsubstituted 3 to 7 membered heterocycloalkyl, unsubstituted aryl, or unsubstituted heteroaryl.
11. The compound of claim 1 , wherein R 37 is substituted or unsubstituted C 1 -C 8 alkyl or substituted or unsubstituted 2 to 8 membered heteroalkyl.
12. The compound of claim 1 , wherein R 37 is unsubstituted C 1 -C 8 alkyl or unsubstituted 2 to 8 membered heteroalkyl.
13. The compound of claim 1 , wherein R 37 is substituted or unsubstituted C 1 -C 4 alkyl.
14. The compound of claim 1 , wherein R 37 is —CF 3 .
15. The compound of claim 1 , wherein w is 0 or 1.
16. The compound of claim 1 , wherein w is 1.
17. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable excipient.